Outlook Therapeutics, Inc.
OTLK
$2.41
-$0.2901-10.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -43.44M | 21.12M | -46.81M | -75.37M | -94.05M |
| Total Depreciation and Amortization | 116.10K | 115.40K | 114.50K | 113.90K | 96.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -20.48M | -88.69M | -28.10M | 9.48M | 38.63M |
| Change in Net Operating Assets | 7.37M | 3.41M | 8.07M | -3.02M | -9.23M |
| Cash from Operations | -56.43M | -64.05M | -66.73M | -68.79M | -64.55M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 33.10M | 33.10M | -- | -- | 0.00 |
| Total Debt Repaid | -33.82M | -32.91M | -1.10K | -4.30K | -7.40K |
| Issuance of Common Stock | 34.14M | 24.30M | 62.19M | 60.45M | 62.88M |
| Repurchase of Common Stock | -115.00K | -115.00K | -115.00K | -115.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | 33.31M | 24.37M | 62.07M | 60.33M | 62.87M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -23.12M | -39.67M | -4.65M | -8.46M | -1.68M |